Not yet recruiting
A study to compare heart failure medicines in one combined pill with usual care.
2026-526510-90-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source
Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00· Phase 3· Kardigan Inc.· Source
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· AstraZeneca· Source
Recruiting
Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
NCT07792239· Phase 2· Xyra, LLC· Source
Not yet recruiting
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
NCT07612657· Phase 3· VIVUS LLC· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy.
2025-522553-19-00· Phase 2/3· Kardigan Inc.· Source
Recruiting
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-1)
2025-522703-14-00· Phase 3· Amgen Inc.· Source
Recruiting
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy (MARITIME-OSA-2)
2025-522699-94-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686· Phase 3· Amgen· Source
Active, not recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765· Phase 3· Amgen· Source
Recruiting
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
NCT07267949· Phase 2· Acesion Pharma· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with coronary artery disease and preDiabetES. A randomised clinical trial (CASCADES)
2023-508525-27-00· Phase 4· Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy· Source
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375· Phase 2· Novo Nordisk A/S· Source
Recruiting
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800· Phase 2/3· Kardigan, Inc.· Source
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362· Phase 2· Novo Nordisk A/S· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease
2023-506971-89-00· Phase 3· Syn2bio S.A.· Source
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629· Phase 3· Intellia Therapeutics· Source
Active, not recruiting
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333· Phase 2· AskBio Inc· Source
Recruiting
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
NCT05943821· Phase 3· Poznan University of Medical Sciences· Source
Recruiting
The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
NCT05508035· Phase 3· John Paul II Hospital, Krakow· Source
Not yet recruiting
Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left
Atrial Appendage Closure – Chronic Kidney Disease (SAFE LAAC CKD). Comparative Health
Effectiveness Ancillary Study – PILOT
NCT05660811· Phase 4· Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy· Source
Active, not recruiting
Does the use of empagliflozin improve exercise capacity in patients with hypertrophic cardiomyopathy.
2024-517643-31-00· Phase 3· Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy· Source
Enrolling by invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506· Phase 2/3· Cytokinetics· Source
Recruiting
Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure
NCT03445949· Phase 4· National Institute of Cardiology, Warsaw, Poland· Source